Latest Breaking News On - Sutro biopharma inc - Page 13 : vimarsana.com

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRa-targeted ADC, on January 4, 2024

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRa-targeted ADC, on January 4, 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Sutro biopharmaLuveltamab tazevibulinEmily whiteDrug administrationExchange commissionSutro biopharma incFast trackOvarian cancerRare pediatric diseaseSouth sanPrivate securities litigation reform act

Sutro Biopharma to Host Investor Webcast Highlighting

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology.

Sutro biopharmaLuveltamab tazevibulinEmily whiteDrug administrationSutro biopharma incExchange commissionFast trackOvarian cancerRare pediatric diseaseSouth sanPrivate securities litigation reform actNasdaq stroSutro biopharma

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with .

United statesSan diegoSouth san franciscoLuveltamab tazevibulinSoheil meshinchiSutro biopharmaEmily whiteGlobenewswire incExchange commissionAmerican society of hematology annual meetingDrug administrationSutro biopharma incHematology annual meetingAbout luveltamabFast trackOvarian cancer

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesJanet graesserJim wassilJennifer zibudaJakub simonGroupa strepSutro biopharma incFree platform technologyExchange commissionVaxcyte incCorporate communicationsTolerability profile similarExceeded regulatory immunogenicityConfirm potentialCell free platform technologyNon inferiority study

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJakub simonJim wassilJanet graesserJennifer zibudaSutro biopharma incFree platform technologyGroupa strepCorporate communicationsExchange commissionVaxcyte incProof of concept data publishedValent pneumococcal conjugate vaccineTolerability profile similarExceeded regulatory immunogenicityConfirm potential